TG THERAPEUTICS INC
For the period ended Jun 12, 2025. Filed Jun 13, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 12, 2025 · Filed Jun 13, 2025
Use the contents to explore the available documents and sections.
Contents
Proposal
Proposal 1
The votes with respect to the election of the six directors to hold office until the 2026 annual meeting were as follows:
| Director | Votes For | % Voted For | Votes Withheld | % Voted Withheld | Broker Non-Votes |
|---|---|---|---|---|---|
| Michael S. Weiss | 75,488,727 | 85.55% | 12,748,318 | 14.45% | 30,193,346 |
| Laurence N. Charney | 71,087,304 | 80.56% | 17,149,741 | 19.44% | 30,193,346 |
| Yann Echelard | 51,734,184 | 58.63% | 36,502,861 | 41.37% | 30,193,346 |
| Kenneth Hoberman | 53,398,586 | 60.52% | 34,838,459 | 39.48% | 30,193,346 |
| Daniel Hume | 51,965,829 | 58.89% | 36,271,216 | 41.11% | 30,193,346 |
| Sagar Lonial, MD | 47,757,163 | 54.12% | 40,479,882 | 45.88% | 30,193,346 |
Proposal 2
The vote with respect to the ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was as follows:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 117,836,086 | 442,199 | 152,106 | -- |
Proposal 3
The advisory vote to approve the compensation of the Company’s named executive officers was as follows:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 47,864,737 | 39,988,402 | 383,906 | 30,193,346 |
Proposal 4
The vote to approve the amendment to the Company’s 2022 Incentive Plan to increase the number of authorized shares of Common Stock authorized for issuance under the 2022 Incentive Plan from 17,000,000 to 22,000,000 was as follows:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 82,034,592 | 5,788,439 | 414,014 | 30,193,346 |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 104 | The cover page from this Current Report on Form 8-K formatted in Inline XBRL. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.